Skip to main content
Fig. 1 | Archives of Public Health

Fig. 1

From: Evaluating anti-MRSA antibiotic stewardship with a focus on trends in consumption and resistance in a tertiary hospital in Alexandria, Egypt from 2019 to 2023

Fig. 1

Quarterly Trends in the Hospital Consumption of Vancomycin, Linezolid, and Teicoplanin (DDD/1000 Patient-Days) in a Tertiary Hospital in Alexandria, Egypt from 2019 to 2023. This figure presents the quarterly consumption trends of three anti-MRSA antibiotics—Vancomycin, Linezolid, and Teicoplanin—in a tertiary hospital in Alexandria, Egypt from January 2019 to December 2023. Linezolid and Teicoplanin demonstrated rising usage trends, while Vancomycin consumption remained relatively stable. Abbreviations: DDD/1000PD, defined daily doses per 1000 patient-days; β, regression coefficient

Back to article page

Archives of Public Health

ISSN: 2049-3258